Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 13, 2021 - Issue
Submit an article Journal homepage
237
Views
1
CrossRef citations to date
0
Altmetric
Original Research

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia

Manaye Tamrie Derseh1 Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, EthiopiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8632-748XView further author information
ORCID Icon,
Kiflom Solomon2 Ayder Teaching Hospital, College of Health Sciences, Mekelle University, Mekelle, EthiopiaView further author information
,
Wasihun Tamene3 Tikur Anbessa Comprehensive Specialized Hospital (TASH), Federal Ministry of Health (FMOH), Addis Ababa, EthiopiaView further author information
,
Wosenie Beneberu3 Tikur Anbessa Comprehensive Specialized Hospital (TASH), Federal Ministry of Health (FMOH), Addis Ababa, EthiopiaView further author information
,
Ashagrachew Tewabe Yayehrad4 Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, EthiopiaORCID Iconhttps://orcid.org/0000-0001-5122-7684View further author information
ORCID Icon &
Abyou Seyfu Ambaye1 Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, EthiopiaORCID Iconhttps://orcid.org/0000-0002-1598-8395View further author information
ORCID Icon
Pages 821-834 | Published online: 16 Sep 2021

References

  • Prins MH, Lensing AWA, Bauersachs R, et al. Oral Rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. doi:10.1186/1477-9560-11-21
  • Gader AA, Haggaz AED, Adam I. Epidemiology of deep venous thrombosis during pregnancy and puerperium in Sudanese women. Vasc Health Risk Manag. 2009;5(1):85–87.
  • Haile L, Hawaz Y, Assefa G. Risk factors of deep venous thrombosis in duplex and colour Doppler ultrasound at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. East Cent Afr J Surg. 2013;18(2):2073–9990.
  • Buller HR, Prins MH, Lensing AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Eng J Med. 2012;366(14):1287–1297.
  • The EINSTEIN-DVT Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Eng J Med. 2010;363:2499–2510. doi:10.1056/NEJMoa1007903
  • Seaman CD, Smith KJ, Ragni MV. Rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: AUS perspective. Thromb Res. 2013;132:647–651. doi:10.1016/j.thromres.2013.09.015
  • Smock KJ. Update on anticoagulants monitoring practice. University of Utah Department of Pathology: ARUP Laboratories; 2017.
  • Venturini F, Johnson KA. Introduction to pharmacoeconomic principles and application in pharmacy practice. CJHP. 2002;14:6–15.
  • The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Eng J Med. 2012;366:1287–1297. doi:10.1056/NEJMoa1113572
  • National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of deep vein thrombosis and pulmonary embolism: final appraisal determination. 2012.
  • Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman,CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845–851. doi:10.1016/j.amjcard.2012.05.011
  • Bamber L, Muston D, McLeod E, Guillermin A, Lowin J, Patel R. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/ vitamin K antagonist. Thromb J. 2015;13:20. doi:10.1186/s12959-015-0051-3
  • Santos IF, Pereira S, Mcleod E, Guillermin AL, Chatzitheofilou I. Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal. Acta Med Port. 2014;27(5):615–624. doi:10.20344/amp.5257
  • Marques GL, DeFranca AC, Saito AC, et al. Clinical outcomes and costs of rivaroxaban for thromboprophylaxis in acutely ill medical inpatients: a cross-sectional study. Cureus. 2021;13(6). doi:10.7759/cureus.15497
  • Yang L, Wu J. Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalized acute deep vein thrombosis in China. BMJ Open. 2020;10(7):e038433. doi:10.1136/bmjopen-2020-038433
  • Gourzoulidis G, Kourlaba G, Kakisis J, et al. Cost-effectiveness analysis of rivaroxaban for treatment of deep vein thrombosis and pulmonary embolism in Greece. Clin Drug Investig. 2017;37(9):833–844. doi:10.1007/s40261-017-0540-1
  • Hori M, Tanahashi N, Akiyama S, Kiyabu G, Goto R. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting. J Med Econ. 2020;23:252–261. doi:10.1080/13696998.2019.1688821
  • Cowper PA, Sheng S, Lopes RD, et al. Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective results from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2017;2:525–534. doi:10.1001/jamacardio.2017.0065
  • Klarenbach LK, Boucher M, So H, Manns B, Tonelli M. Direct oral anticoagulants for the treatment of venous thromboembolic events: economic evaluation. Ottawa: CADTH technology review; 2016.
  • Mendoza JA, Silva FA, Rangel LM. Cost-effectiveness of new oral anticoagulants and warfarin in atrial fibrillation from adverse events perspective. Rev Colomb Cardiol. 2019;26(2):70–77. doi:10.1016/j.rccar.2018.10.011

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.